National Health Act (Pharmaceutical Benefits – Early Supply) Amendment April 2010 - specification under subsection 84AAA(2) (No. PB 28 of 2010)

Administered by Department of Health, Disability and Ageing

Legislation au F2010L00755 Not in force Legislative Instrument

Legislation content

 

EXPLANATORY STATEMENT

 

NATIONAL HEALTH ACT (PHARMACEUTICAL BENEFITS – EARLY SUPPLY) AMENDMENT APRIL 2010 - SPECIFICATION UNDER SUBSECTION 84AAA(2)

 

INSTRUMENT NUMBER PB 28 OF 2010

NATIONAL HEALTH ACT 1953

 

This instrument amends the determination that lists the medicines for which Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements will not apply when the next supply of the same medicine is obtained in less than 20 days.

 

Part VII of the National Health Act 1953 (the Act) is the legislative basis of the PBS by which the Commonwealth provides reliable, timely, and affordable access to a wide range of medicines for all Australians.

 

Subsection 85(1) provides that benefits are to be provided by the Commonwealth in accordance with Part VII in respect of pharmaceutical benefits.

 

Drugs and medicinal preparations to which Part VII applies are declared by the Minister by legislative instrument under subsection 85(2).

 

Subsection 85(3) authorises the Minister by legislative instrument to determine by reference to strength, type of unit, size of unit, or otherwise, the form or forms of a listed drug.  Subsection 85(5) authorises the Minister by legislative instrument to determine the manner of administration of a form of a listed drug where the form has been determined under subsection 85(3).  Subsection 85(6) authorises the Minister by legislative instrument to determine a brand of a pharmaceutical item.

 

These determinations govern what constitutes a pharmaceutical benefit (defined in subsection 84(1)) under Part VII of the Act.

 

Paragraph 85A(2)(a) authorises the Minister to determine the maximum quantity or number of units that may, in one prescription, be directed to be supplied for all purposes or for a particular purpose.  Paragraph 85A(2)(b) authorises the Minister to determine the maximum number of occasions on which the supply may, in one prescription, be directed to be repeated for all purposes or a particular purpose.

 

Paragraph 84C(4A)(a) of the Act refers to repatriation pharmaceutical benefits supplied under the scheme established under section 91 of the Veterans’ Entitlements Act 1986 or supplied in accordance with a determination made under paragraph 256(1)(c) of the Military Rehabilitation and Compensation Act 2004.

 

Subsection 84AAA(1) of the Act provides that a supply of a pharmaceutical benefit to a person is an early supply of a specified pharmaceutical benefit if:

  • The supply is made within 20 days after the day of a previous supply of the same pharmaceutical benefit to the person (whether or not the previous supply is a supply of a kind described in paragraph 84C(4A)(a));
  • The pharmaceutical benefit is specified in an instrument under subsection 84AAA(2); and
  • The supply does not result from a prescription originating from a hospital or a day hospital facility.

 

The early supply of a specified pharmaceutical benefit includes a supply of a pharmaceutical benefit specified in the instrument, as either a pharmaceutical benefit or a repatriation pharmaceutical benefit within 20 days of a previous supply of the same pharmaceutical benefit to the same person.  The repatriation pharmaceutical benefits supplied under the Repatriation Pharmaceutical Benefits Scheme which are subject to the provisions for early supply of a specified pharmaceutical benefit are those where the repatriation pharmaceutical benefit is the same as a specified pharmaceutical benefit for supply under the PBS.

 

‘Hospital’ is defined in the subsection 3(1) of the Health Insurance Act 1973 to mean a recognised hospital, a private hospital, or a hospital that is declared by the Minister to be a hospital for the purposes of that definition.  ‘Day hospital facility’ is defined in subsection 4(1) of the National Health Act 1953.

 

Subsections 84C(4) and 84C(4A) of the Act regulate the supply or repeated supply of pharmaceutical benefits and repatriation pharmaceutical benefits which are be taken into account in totalling amounts charged for the purpose of demonstrating eligibility for a safety net concession card or safety net entitlement card.

 

Subsection 84C(4AA) of the Act provides that the amount charged for an early supply must not be taken into account when determining eligibility for a concession card or entitlement card, if the supply is for a pharmaceutical benefit specified in the instrument and the supply is not an out-patient medication.  That is, an amount charged for an early supply is not eligible for Safety Net purposes and is excluded when calculating whether the Safety Net threshold is reached, unless it is for an outpatient medication.  Outpatient medication is defined in subsection 84(1) of the Act to mean a drug or medicinal preparation supplied through the out-patient department of a public hospital.

 

Subsection 87(2) of the Act sets out the amounts to be charged to patients for the supply of pharmaceutical benefits.  These provisions form the basis for the patient charges which apply for general benefit prescriptions (currently up to $33.30), concessional benefit prescriptions (currently $5.40), concession card prescriptions (currently $5.40), and entitlement prescriptions (free).  The provisions also set the charges for prescriptions which are an early supply of a pharmaceutical benefit.  Early supply charges do not apply for hospital, day hospital, or out-patient prescriptions.  Charges for prescriptions for repatriation pharmaceutical benefits are treated as for concessional benefit prescriptions and entitlement prescriptions, including in relation to early supply.

 

Section 99 of the Act regulates the amounts that pharmacists and medical practitioners who are approved under the Act to supply pharmaceutical benefits, are entitled to be paid by the Commonwealth for supplying those benefits.  This includes the amount to be paid for prescriptions which are an early supply of a pharmaceutical benefit.

 

This legislative instrument is made under subsection 84AAA(2) of the Act. Subsection 84AAA(2) of the Act provides that the Minister may specify, by legislative instrument, pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act.  Subsection 84AAA(3) provides that the instrument may specify a pharmaceutical item by reference to the circumstances in which a pharmaceutical benefit that has the pharmaceutical item is supplied or any other circumstances in relation to a pharmaceutical benefit that has the pharmaceutical item.

 

The pharmaceutical items in the Instrument are specified by the Minister who can take into account the advice of the Pharmaceutical Benefits Advisory Committee (PBAC).  The PBAC is the independent expert body, established by section 100A of the Act, which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.  PBAC members are selected from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions.  Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.

 

Section 101 of the Act sets out the functions of the PBAC in relation to making recommendations and providing advice to the Minister regarding the medicines to be declared as pharmaceutical benefits under Part VII of the Act, and any other matter concerning Part VII of the Act referred to the PBAC by the Minister.

 

Subsection 101(3AA) requires the PBAC to make recommendations to the Minister about what should be specified in an instrument made under 84AAA(2).

 

This Instrument was made on 24 March 2010 and commences on 1 April 2010.

 

This Instrument is a legislative instrument for the purposes of the Legislative Instruments Act 2003.

 

Details of the Instrument are set out in Attachment 1.

 

This Instrument amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - Specification Under Subsection 84AAA(2), PB No. 30 of 2009.  The Instrument amends the list of items specified under subsection 84AAA(2).  Details of the changes effective from 1 April 2010 are set out in Attachment 2.  The additional items and circumstances effective from 1 April 2010 are described in Table 1, and changes to maximum quantity are described in Table 2. 

 

Consultation regarding implementation of the arrangements for early supply of specified pharmaceutical benefits occurred with Medicare Australia, the Department of Veterans’ Affairs, the Medical Software Industry Association, and peak pharmacy organisations (including the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the Australian Association of Consultant Pharmacy, and the Society of Hospital Pharmacists of Australia).  The PBAC has provided advice on which pharmaceutical benefits should be specified in the Instrument.


ATTACHMENT 1

Section 1: provides that the name of the Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment April 2010 - specification under subsection 84AAA(2) and that the Instrument may also be cited as
No. PB 28 of 2010.

 

Section 2: provides that the Instrument commences on 1 April 2010.

 

Section 3: provides that this Amendment amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - specification under subsection 84AAA(2), No. PB 30 of 2009.

 

Schedule 1:  specifies the pharmaceutical items in the pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act by reference to the drug or medicinal product as declared under subsection 85(2), the form (strength, type, size, etc.) as determined under subsection 85(3), manner of administration as determined under subsection 85(5), maximum quantity or number of units as determined under paragraph 85A(2)(a); maximum repeats as determined under paragraph 85A(2)(b), and any other circumstances that apply under paragraph 84AAA(3)(b) of the Act.

 

ATTACHMENT 2

 

 

Table 1.  Forms added

Lansoprazole

Capsule 30 mg

Tablet 15 mg (orally disintegrating)

 

Table 2.  Maximum quantity changed From To

Lercanidipine

Tablet containing lercanidipine hydrochloride 10 mg

30

28

Tablet containing lercanidipine hydrochloride 20 mg

30

28

Lercanidipine with enalapril

Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg

30

28

Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg

30

28

 

Overview

The National Health Act (Pharmaceutical Benefits – Early Supply) Amendment April 2010 - specification under subsection 84AAA(2), also referred to as PB 28 of 2010, was enacted on 24 March 2010 and commenced on 1 April 2010. This legislative instrument amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - specification under subsection 84AAA(2) by modifying the list of pharmaceutical benefits for which the Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements will not apply when the next supply of the same medicine is obtained in less than 20 days. The instrument was developed under the authority of subsection 84AAA(2) of the National Health Act 1953, with the Minister considering advice from the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC, an independent expert body established under the Act, provides recommendations to the Minister regarding which drugs and medicinal preparations should be available as pharmaceutical benefits. The policy objective of this amendment is to address the problem of early resupply of certain medicines, ensuring that amounts charged for such supplies are not taken into account when determining eligibility for a concession card or entitlement card, unless the supply is for an out-patient medication. The instrument was developed through consultation with relevant stakeholders including Medicare Australia, the Department of Veterans’ Affairs, the Medical Software Industry Association, and peak pharmacy organisations. The changes introduced by this instrument are detailed in Attachment 2, which include the addition of certain pharmaceutical items and adjustments to the maximum quantities for specific drugs. The objective of these amendments is to refine the criteria under which early supply of specified pharmaceutical benefits is applicable, thereby ensuring the efficient and fair administration of the PBS.

Scope and Application

The National Health (Pharmaceutical Benefits – Early Supply) Amendment April 2010 - specification under subsection 84AAA(2) Instrument No. PB 28 of 2010 amends the list of pharmaceutical benefits for which the Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements do not apply when the next supply of the same medicine is obtained within 20 days. This legislative instrument operates under Part VII of the National Health Act 1953, which governs the PBS and the provision of reliable, timely, and affordable access to medicines for all Australians. The instrument is applicable to pharmaceutical benefits and repatriation pharmaceutical benefits, excluding those supplied by hospitals or day hospital facilities. The Minister specifies the pharmaceutical items and circumstances under subsection 84AAA(2) of the Act, considering the advice from the Pharmaceutical Benefits Advisory Committee. The changes outlined in the instrument, effective from 1 April 2010, include the addition of certain forms of Lansoprazole and adjustments to the maximum quantity for Lercanidipine and its combination with enalapril maleate. The instrument does not alter the charges for general benefit prescriptions, concessional benefit prescriptions, concession card prescriptions, or entitlement prescriptions, including those for early supply, except for the exclusion of early supply amounts from Safety Net calculations unless they pertain to out-patient medication.

Key Provisions

The main operative sections of the National Health (Pharmaceutical Benefits – Early Supply) Amendment April 2010 – Specification under Subsection 84AAA(2) are sections 84AAA(1) and 84AAA(2). Section 84AAA(1) defines what constitutes an 'early supply' of a specified pharmaceutical benefit, while section 84AAA(2) allows the Minister to specify, by legislative instrument, pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act. This Amendment specifies certain pharmaceutical benefits for which PBS Safety Net entitlements will not apply if the next supply of the same medicine is obtained in less than 20 days. It amends the list of items specified in the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – Specification under Subsection 84AAA(2), PB No. 30 of 2009. The Act imposes specific obligations and requirements on various parties involved in the pharmaceutical supply chain. The Minister, as authorised by subsection 84AAA(2), is required to specify pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act. The Pharmaceutical Benefits Advisory Committee (PBAC) provides advice to the Minister on which pharmaceutical benefits should be specified in the Instrument. The PBAC's recommendations and advice are based on their expertise and the interests of consumers, health economists, and various health professionals. Pharmacists and medical practitioners who supply pharmaceutical benefits under the Act are entitled to be paid by the Commonwealth for their services, including for prescriptions which are an early supply of a pharmaceutical benefit. These obligations and requirements ensure that the pharmaceutical benefits scheme operates effectively and that patients receive appropriate access to medications. There are no specific offences, penalties, or civil/criminal consequences outlined in this Amendment for breaches of its provisions. However, the National Health Act 1953 and other related legislation may contain provisions that address non-compliance with the Act or its regulations. For example, subsection 114(1) of the Act provides that a person who contravenes a provision of the Act or its regulations is guilty of an offence and may be subject to a penalty. The maximum penalty for an individual is generally five penalty units ($1,100 as of April 2021) for each offence, while the maximum penalty for a body corporate is generally fifty penalty units ($55,000 as of April 2021) for each offence. It is essential to consult the relevant legislation for specific details on penalties and enforcement mechanisms.

Legal classification tags

Area of Law
Health Law
Pharmaceutical Law
Instrument
Statutory Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Licensing & Registration
Reporting & Disclosure Obligations
Enforcement Powers
Compliance Obligations
Catchwords
Pharmaceutical Benefits

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.